Cancer, Data and the Fallacy of the $1000 Genome – Forbes

Puts some of the hype on cancer genomics in context, citing Dr. Mark Boguski, an Associate Professor at Harvard Medical School (for his neat graphical cv, clic here). Quote:

Here’s the challenge facing the treating physician:  It costs a lot more than $1000 to sequence a genome.  Sure, costs continue to fall but the price today to sequence [minimally] two genomes – from tumor and normal tissue, to analyze the data and have an oncologist interpret that data in terms of clinical recommendation – is between $25K and $100K.  That cost is not covered by insurance.  And most importantly, you have to know someone.  If we set the total current sequencing capacity in the US against the number of new cancers each year we can only sequence a few percent of those patients.  To get your cancer genome sequenced you have to have a friend at a genome center who can do the work, perform the analysis and work with a clinical oncologist to optimize therapy.  This isn’t going to change any time soon.

Cancer, Data and the Fallacy of the $1000 Genome – Forbes.


What do you think?

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s